Align Technology consensus in focus, NASDAQ shares under analyst scrutiny

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 11:38.

Align Technology (US0162551016) starts Tuesday with its NASDAQ listing and a firmly established role in the U.S. medical devices sector. The stock sits in global portfolios as a specialist in clear aligners and digital orthodontics, with the shares closely watched by retail and institutional investors around scheduled earnings dates and analyst revisions.

What analysts track today

Analyst coverage on Align Technology typically focuses on revenue growth in its clear aligner segment and on margins in its digital scanner and services business. Houses such as Goldman Sachs, Morgan Stanley or UBS usually monitor trends in case volumes, average selling prices and geographic expansion when they update ratings or price targets for the NASDAQ-listed shares.

Consensus models often break down Align Technology’s top line into clear aligners and systems, reflecting the importance of Invisalign-branded treatments and the company’s scanners in dental practices worldwide. Analysts frequently compare quarterly numbers against prior guidance ranges and historical growth rates, especially in North America and Europe, where Align Technology has built a strong franchise among orthodontists and general practitioners.

Consensus and peer comparison on Tuesday

For Tuesday’s focus, the consensus picture around Align Technology centers on expectations for upcoming quarterly results and how the stock compares with dental peers such as Straumann Group or Dentsply Sirona in terms of growth, profitability and valuation. Analysts often highlight Align Technology’s exposure to consumer discretionary spending, given that clear aligner treatments can be elective and influenced by household budgets and macroeconomic trends.

In the broader medical devices and dental segment, investors benchmark Align Technology’s valuation metrics such as price-to-earnings and enterprise value-to-sales against peers active in implants, restorative dentistry and orthodontic equipment. The stock’s performance relative to indices like the S&P 500 and NASDAQ-100 helps analysts judge whether the market prices in above-average growth or embeds caution around patient demand and practice investments in digital tools.

The product behind the stock

Align Technology generates most of its revenue through its Invisalign clear aligner system, a series of custom-made, removable appliances designed to straighten teeth over time. The company complements this with iTero intraoral scanners and related digital services, which enable dentists and orthodontists to capture precise 3D images and plan treatments digitally.

Where the stock trades today

Align Technology shares (US0162551016) trade on the NASDAQ in U.S. dollars; the current price and exact time stamp for June 30, 2026 are subject to the latest exchange quote and intraday movement.

Disclaimer: This article is for information purposes only and does not contain investment advice, recommendations or solicitations to buy or sell securities. All data and assessments are based on publicly available information as of June 30, 2026 and may change without notice. Retail investors should consider their own financial situation and consult qualified advisors before making investment decisions.